Were the Kymera Therapeutics (KYMR) share sales pre-planned under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Atlas funds on December 11, 2025. Such plans schedule trades in advance, reducing the significance of near-term market timing decisions by the insider.

Rule 10b5-1 plan drives 285,684 Kymera (KYMR) share sale by Atlas funds

Q: Who actually sold the Kymera Therapeutics (KYMR) shares reported in this Form 4?

The shares were sold by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. . Bruce Booth is a member of the general partner entities of these funds and reports the trades as indirect interests, disclaiming Section 16 beneficial ownership except for any pecuniary interest.

Q: What price range did the Kymera Therapeutics (KYMR) shares sell for in these transactions?

The reported prices are weighted averages for trades executed within ranges. Footnotes indicate sales occurred at prices roughly from $119.08 up to $130.05 per share, with each line item representing averages over multiple individual transactions within narrower bands.

Q: How many separate sale transactions are included in this Kymera Therapeutics (KYMR) Form 4?

The transaction summary shows 22 sale transactions of Kymera common stock. Each represents an open-market sale at a reported weighted average price, with detailed ranges for the actual trade prices provided in the accompanying footnotes to the filing.

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. reported that entities associated with director Bruce Booth sold a total of 285,684 shares of Kymera common stock on June 25 in open-market transactions. The sales were executed by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, and are reported as indirect interests, with Booth disclaiming Section 16 beneficial ownership except for any pecuniary interest.

Insights

Large, pre-planned indirect sales via funds tied to a Kymera director.

Entities affiliated with director Bruce Booth sold 285,684 shares of Kymera Therapeutics common stock in a series of open-market transactions on June 25. The trades were executed by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., not by Booth personally.

The filing states these transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating they were pre-arranged rather than opportunistic. Prices were reported as weighted averages within ranges roughly between $119.08 and $130.05 per share.

Booth reports the trades as indirect holdings and disclaims Section 16 beneficial ownership beyond any pecuniary interest, which is common for venture-backed structures. There are no derivative positions disclosed in this filing, and the overall impact depends on the funds’ broader ownership levels, which are not detailed here.

Insider Trade Summary 10b5-1

Net Seller: 285,684 shares ($34,812,909)

Net Sell 22 txns

Insider Booth Bruce

Role null

Sold 285,684 shs ($34.81M)

Type	Security	Shares	Price	Value
Sale	Common Stock	37,179	$119.71	$4.45M
Sale	Common Stock	112,299	$120.66	$13.55M
Sale	Common Stock	40,774	$121.38	$4.95M
Sale	Common Stock	4,977	$122.67	$611K
Sale	Common Stock	10,860	$123.62	$1.34M
Sale	Common Stock	11,711	$124.61	$1.46M
Sale	Common Stock	3,716	$125.82	$468K
Sale	Common Stock	1,609	$126.71	$204K
Sale	Common Stock	25,075	$127.37	$3.19M
Sale	Common Stock	2,197	$128.69	$283K
Sale	Common Stock	337	$129.61	$44K
Sale	Common Stock	5,144	$119.71	$616K
Sale	Common Stock	15,660	$120.66	$1.89M
Sale	Common Stock	5,689	$121.38	$691K
Sale	Common Stock	698	$122.67	$86K
Sale	Common Stock	1,517	$123.62	$188K
Sale	Common Stock	1,639	$124.61	$204K
Sale	Common Stock	522	$125.82	$66K
Sale	Common Stock	223	$126.71	$28K
Sale	Common Stock	3,507	$127.37	$447K
Sale	Common Stock	305	$128.69	$39K
Sale	Common Stock	46	$129.61	$6K

Holdings After Transaction: Common Stock — 3,075,906 shares (Indirect, See footnote)

Footnotes (1)

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.08 to $120.0798 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (4) through (13). These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.08 to $121.0794 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.08 to $122.0731 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.0858 to $123.08 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.09 to $124.08 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.09 to $125.0292 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.1194 to $126.115 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.13 to $127.0511 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.30 to $128.2975 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.3008 to $129.2819 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.3041 to $130.05 inclusive. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.

Key Figures

Shares sold: 285,684 shares Highest reported sale price: $130.05 per share Lowest reported sale price: $119.08 per share +2 more

5 metrics

Shares sold 285,684 shares Total Kymera common stock sold in open-market transactions on June 25

Highest reported sale price $130.05 per share Upper end of footnote price ranges for June 25 sales

Lowest reported sale price $119.08 per share Lower end of footnote price ranges for June 25 sales

Number of sale transactions 22 transactions Total sale entries summarized as net-sell in transaction summary

10b5-1 plan adoption date December 11, 2025 Date Atlas funds adopted the Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, weighted average price, Section 16 beneficial ownership, pecuniary interest

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions..."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Section 16 beneficial ownership regulatory

"The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held..."

pecuniary interest financial

"disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 09:56 PM Accepted by SEC EDGAR 06/25/2026 - 09:56 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Booth Bruce

(Last)

(First)

(Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, FLOOR 4

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/25/2026		S⁽¹⁾		37,179	D	$119.71⁽²⁾	3,075,906	I	See footnote⁽³⁾
Common Stock	06/25/2026		S⁽¹⁾		112,299	D	$120.66⁽⁴⁾	2,963,607	I	See footnote⁽³⁾
Common Stock	06/25/2026		S⁽¹⁾		40,774	D	$121.38⁽⁵⁾	2,922,833	I	See footnote⁽³⁾
Common Stock	06/25/2026		S⁽¹⁾		4,977	D	$122.67⁽⁶⁾	2,917,856	I	See footnote⁽³⁾
Common Stock	06/25/2026		S⁽¹⁾		10,860	D	$123.62⁽⁷⁾	2,906,996	I	See footnote⁽³⁾
Common Stock	06/25/2026		S⁽¹⁾		11,711	D	$124.61⁽⁸⁾	2,895,285	I	See footnote⁽³⁾
Common Stock	06/25/2026		S⁽¹⁾		3,716	D	$125.82⁽⁹⁾	2,891,569	I	See footnote⁽³⁾
Common Stock	06/25/2026		S⁽¹⁾		1,609	D	$126.71⁽¹⁰⁾	2,889,960	I	See footnote⁽³⁾
Common Stock	06/25/2026		S⁽¹⁾		25,075	D	$127.37⁽¹¹⁾	2,864,885	I	See footnote⁽³⁾
Common Stock	06/25/2026		S⁽¹⁾		2,197	D	$128.69⁽¹²⁾	2,862,688	I	See footnote⁽³⁾
Common Stock	06/25/2026		S⁽¹⁾		337	D	$129.61⁽¹³⁾	2,862,351	I	See footnote⁽³⁾
Common Stock	06/25/2026		S⁽¹⁾		5,144	D	$119.71⁽²⁾	559,524	I	See footnote⁽¹⁴⁾
Common Stock	06/25/2026		S⁽¹⁾		15,660	D	$120.66⁽⁴⁾	543,864	I	See footnote⁽¹⁴⁾
Common Stock	06/25/2026		S⁽¹⁾		5,689	D	$121.38⁽⁵⁾	538,175	I	See footnote⁽¹⁴⁾
Common Stock	06/25/2026		S⁽¹⁾		698	D	$122.67⁽⁶⁾	537,477	I	See footnote⁽¹⁴⁾
Common Stock	06/25/2026		S⁽¹⁾		1,517	D	$123.62⁽⁷⁾	535,960	I	See footnote⁽¹⁴⁾
Common Stock	06/25/2026		S⁽¹⁾		1,639	D	$124.61⁽⁸⁾	534,321	I	See footnote⁽¹⁴⁾
Common Stock	06/25/2026		S⁽¹⁾		522	D	$125.82⁽⁹⁾	533,799	I	See footnote⁽¹⁴⁾
Common Stock	06/25/2026		S⁽¹⁾		223	D	$126.71⁽¹⁰⁾	533,576	I	See footnote⁽¹⁴⁾
Common Stock	06/25/2026		S⁽¹⁾		3,507	D	$127.37⁽¹¹⁾	530,069	I	See footnote⁽¹⁴⁾
Common Stock	06/25/2026		S⁽¹⁾		305	D	$128.69⁽¹²⁾	529,764	I	See footnote⁽¹⁴⁾
Common Stock	06/25/2026		S⁽¹⁾		46	D	$129.61⁽¹³⁾	529,718	I	See footnote⁽¹⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.08 to $120.0798 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (4) through (13).

3. These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.08 to $121.0794 inclusive.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.08 to $122.0731 inclusive.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.0858 to $123.08 inclusive.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.09 to $124.08 inclusive.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.09 to $125.0292 inclusive.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.1194 to $126.115 inclusive.

10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.13 to $127.0511 inclusive.

11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.30 to $128.2975 inclusive.

12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.3008 to $129.2819 inclusive.

13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.3041 to $130.05 inclusive.

14. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.

Remarks:

Due to the 30 line limitation in Table I, this report is being filed across two forms. This is the second of two filings.

	/s/ Ommer Chohan, Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

How many Kymera Therapeutics (KYMR) shares were sold in this Form 4?

The filing reports that entities linked to director Bruce Booth sold 285,684 shares of Kymera Therapeutics common stock. These were open-market transactions executed across multiple trades on June 25 under a pre-arranged Rule 10b5-1 trading plan.

Who actually sold the Kymera Therapeutics (KYMR) shares reported in this Form 4?

The shares were sold by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P.. Bruce Booth is a member of the general partner entities of these funds and reports the trades as indirect interests, disclaiming Section 16 beneficial ownership except for any pecuniary interest.

What price range did the Kymera Therapeutics (KYMR) shares sell for in these transactions?

The reported prices are weighted averages for trades executed within ranges. Footnotes indicate sales occurred at prices roughly from $119.08 up to $130.05 per share, with each line item representing averages over multiple individual transactions within narrower bands.

Does Bruce Booth directly own the Kymera Therapeutics (KYMR) shares sold in this Form 4?

No. The filing explains the shares are owned directly by Atlas venture funds, and Bruce Booth is a member of their general partner entities. He disclaims Section 16 beneficial ownership of those securities, except to the extent of his pecuniary interest, if any.

How many separate sale transactions are included in this Kymera Therapeutics (KYMR) Form 4?

The transaction summary shows 22 sale transactions of Kymera common stock. Each represents an open-market sale at a reported weighted average price, with detailed ranges for the actual trade prices provided in the accompanying footnotes to the filing.